Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical Studies by Tadic, M et al.
Journal of
Clinical Medicine
Review
Sex and Heart Failure with Preserved Ejection
Fraction: From Pathophysiology to Clinical Studies
Marijana Tadic 1,*, Cesare Cuspidi 2, Sven Plein 3, Evgeny Belyavskiy 1, Frank Heinzel 1 and
Maurizio Galderisi 4
1 Department of Internal Medicine and Cardiology, Charité–Universitätsmedizin Berlin, Augustenburgerplatz
1, 13353 Berlin, Germany; Evgeny.Belyavskiy@charite.de (E.B.); Frank.heinzel@charite.de (F.H.)
2 Clinical Research Unit, University of Milan-Bicocca and Istituto Auxologico Italiano,
Viale della Resistenza 23, 20036 Meda, Italy; cesare.cuspidi@unimib.com
3 Department of Biomedical Imaging Science, Leeds Institute of Cardiovascular and Metabolic Medicine,
University of Leeds, Leeds LS2 9JT, UK; s.plein@leeds.ac.uk
4 Department of Advanced Biomedical Sciences, Federico II University Hospital, Edificio 1 Via Pansini 5,
80131 Naples, Italy; Maurizio.gaderi@unina.com
* Correspondence: marijana_tadic@hotmail.com
Received: 7 April 2019; Accepted: 29 May 2019; Published: 4 June 2019


Abstract: Heart failure with preserved ejection fraction (HFpEF) represents the most frequent form of
heart failure in women, with almost two-fold higher prevalence than in men. Studies have revealed
sex-specific HFpEF pathophysiology, and suggested the possibility of a sex-specific therapeutic
approach in these patients. Some cardiovascular risk factors, such as arterial hypertension, obesity,
diabetes mellitus, coronary artery disease, atrial fibrillation, and race, show specific features that might
be responsible for the development of HFpEF in women. These risk factors are related to specific
cardiovascular changes—left ventricular diastolic dysfunction and hypertrophy, ventricular–vascular
coupling, and impaired functional capacity—that are related to specific cardiac phenotype and HFpEF
development. However, there is no agreement regarding outcomes in women with HFpEF. For
HFpEF, most studies have found higher hospitalization rates for women than for men. Mortality
rates are usually not different. Pharmacological treatment in HFpEF is challenging, along with many
unresolved issues and questions raised. Available data on medical therapy in patients with HFpEF
show no difference in outcomes between the sexes. Further investigations are necessary to better
understand the pathophysiology and mechanisms of HFpEF, as well as to improve and eventually
develop sex-specific therapy for HFpEF.
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1. Introduction
Heart failure (HF) represents a large health burden because of its increasing prevalence, significant
morbidity and mortality, and constantly increasing expenses of treatment [1]. The introduction of new
entities—heart failure with preserved ejection fraction (HFpEF), and, later, heart failure with mid-range
ejection fraction (HFmEF)—has significantly broadened the HF spectrum. Studies published in the
last few years have revealed that cardiovascular disease (CVD) is the main cause of death among
women, and more women than men die from CVD [2]. For HFpEF, there is clear evidence of important
differences between the sexes. Namely, the prevalence of HFpEF ranges between 40 and 70% of all
patients with HF, but the ratio between women and men is 2:1 [3,4]. Several authors have tried to ascribe
this difference to comorbidities such as obesity and diabetes, which are more prevalent in women.
However, this is not sufficient to explain the significantly higher HFpEF prevalence and mortality in
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women. The main problem for the assessment of sex influence on HFpEF morbidity and mortality is
the fact that, in majority of published studies, the assessment of the sex effect was retrospective.
The data regarding differences in pathophysiology, outcomes, and treatment in women and men
with HFpEF are scarce. One of the main problems in the assessment of sex and its impact on HFpEF
morbidity and mortality is the retrospective design of most studies.
PubMed, Medline, OVID, Cochrane, and EMBASE databases were searched for studies published
in the English language from January 1990 through to February 2019, using the following keywords:
“heart failure with preserved ejection fraction,” “HFpEF,” “gender,” “sex,” “prevalence,” “risk factors,”
“left ventricle,” “diastolic function,” “renin-angiotensin inhibitors,” “angiotensin receptor blockers,”
“beta-blockers,” and “aldosterone.”
The aim of this systematic review article is to provide a comprehensive overview of currently known
disparities in epidemiology, pathophysiology, and recent clinical studies regarding hemodynamic
changes, cardiac remodeling, treatment, and outcome.
2. Epidemiology
The latest report of the American Heart Association included 110,621 HF patients, 50% (55,083) of
whom had HF with reduced EF (HFrEF), 14% (15,184) HFmEF, and 36% (40,354) HFpEF. The report
emphasized three important findings: HFpEF was more prevalent in women compared with men,
there was no difference in HFpEF incidence between the sexes, and HFpEF was the most common
subtype in women with HF [5]. These data agree with other recently published studies. Goyal et al.
included 1,889,608 hospitalizations due to HFpEF, and showed that the prevalence of hospitalizations
was significantly higher among women than men (64% vs. 36%) [6]. Harada et al. also reported
significantly higher prevalence of HFpEF in women than in men (529 women vs. 204 men, p < 0.001) [7].
Duca et al. confirmed these findings in a small study that included 260 HFpEF patients (181 females
and 79 males) [8]. It should be emphasized that the majority of trials that investigated the effect of
medications on HFpEF performed adjustments for sex in order to account for sex-related effects [9].
A recently published study revealed that the lifetime risk of HFpEF at index ages 45 through
90 was similar in men and women, whereas the lifetime risk of HFrEF was 1.8-fold higher in men
compared with women [10]. The lifetime risks of HFpEF and HFrEF were similar in men while women
had a substantially higher lifetime risk of HFpEF than HFrEF [10]. Interestingly, the lifetime risks of
HFpEF and HFrEF were not substantially lower at higher index ages in men and women. Overall,
current evidence clearly shows that sex-specific prevalence exists in HFpEF patients.
3. Pathophysiology
Pathophysiological mechanisms that could explain sex-related differences in HFpEF can
be separated into several groups: (i) hormonal differences; (ii) bio-hormonal system activity
(renin-angiotensin-aldosterone system, sympathetic nervous system, prostaglandin/prostacyclin,
oxidative stress, inflammation); (iii) differences in cardiovascular risk factors and predisposing
diseases important for HFpEF development (hypertension, obesity, diabetes and insulin resistance,
coronary artery disease, atrial fibrillation); and (iv) race, which has been an important predictor of
HFpEF development or worse outcome in HFpEF patients in recent studies. The central illustration
(Figure 1) illustrates the proposed sex-specific pathophysiological mechanisms responsible for HFpEF
development in women. Figure 2 shows the influence of estrogen deficiency on left ventricular
(LV) remodeling and development of HFpEF. All these mechanisms could induce a sex-specific
hemodynamic response, and, ultimately, different functional and structural LV remodeling in men and
women, which could partly explain the variations in HFpEF induced by sex.
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3.1. Hormonal Differences
The MESA (Multi-ethnic study of Atherosclerosis) study, after a nine year follow-up, reported
that the androgenic profile, characterized by higher free testosterone and lower sex hormone binding
globulin, was related to a higher increase in LV mass in both sexes, whereas a greater increase in
ratio between LV mass and volume was found only in women [11]. LVEF (Left ventricular ejection
fraction) remained higher in women than in men for the whole duration of the study. These changes
are consistent with the known effects of menopause, after which LV mass, but not LV volume,
increases, leading to small and rigid LVs. Increased LV stiffness induces LV diastolic dysfunction and
further HFpEF.
The same study showed that a higher testosterone/estradiol ratio and lower estradiol levels were
associated with the increased risk of HFrEF, but not with HFpEF [12]. The authors hypothesized
that the reduced estradiol during menopause affects vascular and cardiac remodeling, inducing more
HFrEF than HFpEF. However, there are also many possible confounders in the MESA study that could
interfere with the relationship between hormones and HFpEF occurrence.
Li et al. summarized the effects of estrogen on LV diastolic function: regulative function of
mitochondria, cardiac hypertrophy, Ca2+ homeostasis, and titin isoform switches [13]. Considering
the fact that LV diastolic dysfunction represents the cornerstone of HFpEF, the lack of estrogen could
partly explain higher HFpEF in women.
3.2. Bio-Hormonal Systems
Bio-hormonal systems could be the leading causes of sex-specific differences in cardiovascular
diseases. Studies have shown that sex differences exist in the aging pattern of the renin-angiotensin-
aldosterone system (RAAS) [13]. Significantly lower angiotensin-converting enzyme (ACE) serum
activity was found in older men compared to older women [14]. Furthermore, significantly lower ACE
serum activity was detected in older men compared to younger men. In contrast, in women, there
were no differences in ACE serum depending on age, but there was significantly higher ACE-2 serum
activity in older women compared to younger women [14]. Thoering et al. demonstrated that men
had a higher aldosterone level and a lower adrenal response to exogenous angiotensin II infusion than
women [15]. These constitutive sex differences in the regulation of aldosterone were related to higher
extracellular volume and higher blood pressure in men than in women [15].
RAAS is associated with LV hypertrophy as well as with LV diastolic dysfunction [16,17], and
both are associated with LV remodeling, which finally induces HFpEF. These observations suggest
mechanisms by which variations in bio-hormonal systems could induce sex variations in HFpEF
patients, and may require sex-determined therapeutic approaches.
The sympathetic nervous system (SNS) is also sex-dependent in several ways: (i) the regulatory
system for SNS activation is less sensitive to excitation and more sensitive to inhibition in women than in
men; (ii) cardiopulmonary induced SNS inhibition is higher in women, which could result in better renal
excretory function; (iii) reduced sensitivity to adrenergic nerve stimulation, but not to noradrenaline,
indicates that sex-induced SNS variations could protect females against SNS hyperactivation; and (iv)
women are less sensitive and/or less responsive to adrenal medullary activation, which helps them in
the situations of increased stress [17–19].
Previous studies showed that SNS overactivity was related to impaired LV diastolic function [20]
and LV hypertrophy [21], the major determinants of HFpEF. However, one should also not forget
that RAAS and SNS overactivation are related to arterial hypertension, obesity, and diabetes/insulin
resistance, which are main risk factors of HFpEF development in women [22–24].
Besides well-known bio-hormonal systems, systemic microvascular endothelial inflammation
has lately been cited as an important risk factor of HFpEF [25]. Inflammation decreases nitric
oxide bioavailability, the cyclic guanosine monophosphate level, and protein kinase G activity in
cardiomyocytes. These changes induce interstitial fibrosis, and subsequently LV hypertrophy and
elevated resting tone in cardiomyocytes due to hypophosphorylation of titin. Increased LV stiffness
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induces elevation of LV filling pressure and HFpEF development [25]. Recent studies have shown
that sex-biased microRNA could be responsible for a different response to systemic inflammation
that induces microvascular defects related to HFpEF [26]. Sex-biased microRNAs are regulated by
estrogen in their transcription and processing, or are expressed from loci on the X chromosome due to
incomplete X chromosome inactivation. Estrogen-induced microRNAs principally have a protective
function, which is why menopausal estrogen deficiency results might contribute to the molecular
mechanisms that increase the risk of HFpEF in women [26].
3.3. Cardiovascular Risk Factors
Obesity, hypertension, diabetes, coronary heart disease, atrial fibrillation, anemia, chronic
obstructive pulmonary disease, renal dysfunction, and history of chemo- and radiotherapy are
important risk factors of HFpEF development in both sexes, but it seems that some of these factors are
more significant among females (Table 1). A recent study of 1204 HFpEF patients from Asia showed
that 70% of the patients had ≥2 co-morbidities, most commonly hypertension (71%), anemia (57%),
chronic kidney disease (50%), diabetes (45%), coronary artery disease (29%), atrial fibrillation (29%),
and obesity (26%) [27]. In the next segment, we will particularly consider these comorbidities in the
light of sex differences.
3.3.1. Hypertension
Hypertension represents one of the major factors responsible for HFpEF development [22].
Pandey et al. reported that hypertension was more prevalent in women than in men in all age
groups [10]. However, it was statistically significantly higher only in the oldest group of patients
(>75 years) [10]. Hoyal et al. reported that arterial hypertension was more prevalent in women
than in men with HFpEF, and the difference was more pronounced in women older than 75 years of
age [6]. Levi et al. reported similar findings, and calculated that hypertension increased the risk of HF
three-fold in women, compared with two-fold in men [28]. However, at that time the HFpEF entity was
unknown, and, therefore, the results relate to HFrEF. A large population of postmenopausal women
showed that hypertension represented a significant risk factor of HFpEF development in women of all
races (white, African American, and Hispanic) [29].
Table 1. Sex-specific differences in risk factors in HFpEF patients.
Reference Sample Size Women/Men (%) Study Type Main Findings
Goyal et al.
[6]
1,889,608 pts
hospitalized for
HFpEF
1,208,763 (64) Shortfollow-up
Arterial hypertension, obesity, and anemia
were significantly more prevalent among
women than men with HFpEF. Diabetes was
more prevalent in women younger than 75
years and in men older than 75 years. Atrial
fibrillation and coronary artery disease were
more prevalent in men.
Harada et al.
[7] 733 HFpEF pts 529 (72) Cross-sectional
Obesity (BMI > 25 kg/m2), diabetes, coronary
artery disease and atrial fibrillatio were more
frequent in men than in women with HfpEF.
Duca et al. [8] 260 HFpEF pts 181 (70) 30 monthfollow-up
No difference in cardiovascular risk factors
between women and men with HFpEF, except
smoking and chronic obstructive lung disease.
Pandey et al.
[10] 12,417 subjects 6854 (55.2)
11.6 year
follow-up
The lifetime risk of HFpEF did not differ
between women and men.
Eaton et al.
[29]
42,170
postmenopausal
women
All 13.2 yearfollow-up
Hypertension, diabetes, and obesity were
independent predictors only of HFpEF, but not
HFrEF. The white race, and not African
American and Hispanic, was associated with
both, HFpEF and HFrEF.
BMI—body mass index, HFpEF—heart failure with preserved ejection fraction, HFrEF—heart failure with reduced
ejection fraction.
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The importance of arterial hypertension in elderly women underlines the significance of isolated
systemic hypertension, typical of this population of patients. A higher augmentation index between
peripheral and central blood pressure in elderly women, compared with men, could explain more
pronounced target organ damage, including LV hypertrophy [30]. Women have different adaptation
to pressure overload than men, with more prevalent concentric than eccentric LV remodeling [31].
Higashi et al. reported a significant correlation between carotid augmentation index—as a parameter
of arterial stiffness—and LV diastolic dysfunction only in women, but not men [32]. Mengden et al.
summarized the relationship between isolated systolic hypertension, ventriculo-arterial coupling, and
LV diastolic dysfunction in elderly women, and stated that this association could be the cornerstone of
HFpEF in females [33].
3.3.2. Obesity
Our study group has recently reviewed mechanisms that connect obesity and HFpEF, and we
have emphasized the importance of sex in HFpEF development [23]. A large study followed 22,681
participants for 12 years, and revealed that body mass index (BMI) and insulin resistance were more
strongly associated with the risk of HFpEF than HFrEF development in women, but not in men [34].
The same study showed that waist circumference was independently associated with HFpEF occurrence
in both sexes. Goyal et al. demonstrated that obesity was significantly more prevalent among women
than men with HFpEF [6]. However, Harada et al. showed that obesity, defined as a BMI > 25 kg/m2,
was more prevalent in men than in women with HFpEF [7]. However, BMI correlated with plasma
brain natriuretic peptide (BNP) only in women, but not in men with HFpEF [7].
In a large population of postmenopausal women whose obesity was followed for 13 years,
there was an independent predictor of HFpEF, but not HFrEF [29]. A recently published study that
investigated the impact of the pattern of regional adipose deposition (abdominal, cardiac, intermuscular)
on cardiorespiratory fitness in patients with HFpEF revealed that abdominal subcutaneous fat was
inversely associated with functional capacity in older patients with HFpEF [35]. Furthermore,
intra-abdominal fat was the strongest independent predictor of reduced functional capacity in these
patients [35]. This could explain prominent symptoms and increased mortality in obese women
with HFpEF.
3.3.3. Diabetes and Insulin Resistance
McHugh et al. have recently explained the complex relationship between diabetes and HFpEF [24].
The authors provided several mechanisms that included sodium retention and consequent volume
overload, increased pro-inflammatory cytokines, poor skeletal muscle function, and impaired
cardiorespiratory fitness [24].
Savji et al. reported that fasting glucose was an independent predictor of HFpEF occurrence only
in women, but not in men [34]. Interestingly, the homeostatic model assessment (HOMA) index—a
parameter of insulin resistance—was a predictor of HFpEF development only in men, but not in
women [34]. Goyal et al. reported higher prevalence of diabetes only among younger patients
(<75 years) hospitalized due to HFpEF [6]. Interestingly, in smaller studies that included fewer than
1000 HFpEF patients, the authors found significantly higher prevalence of diabetes among men than
women [7,36], or reported no difference between the sexes [8].
3.3.4. Coronary Artery Disease
Coronary artery disease is a dominant risk factor of the development of HFpEF in men. However,
its influence in women should not be neglected. This was confirmed in large studies which showed that
coronary artery disease, prior percutaneous coronary intervention, or coronary artery bypass grafting
were significantly more frequent in men than in women hospitalized with symptoms of HFpEF [6].
Nakada et al. also reported that ischaemic heart disease was a more frequent cause of HFpEF among
males than females (17.5% vs. 30.6%) [36]. Other authors reported similar findings by defining
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coronary artery disease as myocardial infarction [7,37]. Eaton et al. did not find a correlation between
previous myocardial infarction and hospitalization due to HFpEF, but only HFrEF, in postmenopausal
women [29].
One should not forget the importance of coronary microvascular dysfunction and ischemia on
HFpEF [38]. The ARIC study (the Atherosclerosis Risk in Communities Study) recently showed that
retinal microvascular dysfunction was a long-term risk factor of mortality and ischemic stroke in both
sexes, while microvascular heart disease was an independent predictor only in women, but not in
men [39].
3.3.5. Atrial Fibrillation
In atrial fibrillation, women seem to have a larger LA volume index and worse LA pump function
than men [40]. Furthermore, atrial fibrillation seems to increase the risk of HF mostly in women, but
not in men [41]. The TOPCAT trial (Treatment of Preserved Cardiac Function HF with an Aldosterone
Antagonist Trial) revealed that atrial fibrillation was related to the risk of hospitalization in both sexes
with HFpEF, but more strongly in women [42]. Lam et al. showed the association between the sexes
regarding atrial fibrillation, lower cardiorespiratory fitness, natriuretic peptide elevation, and left
atrial enlargement in HFpEF [43]. The authors concluded that atrial fibrillation in women might be
associated with a greater risk of adverse events than in men. This is yet to be clarified, because other
investigations have denied the role of atrial fibrillation in HFpEF in women and reported similar
prevalence of this arrhythmia between the sexes [36], or even a higher prevalence in men [6,7].
3.4. Race
The influence of race on the development and outcome of HFpEF in the sexes has not been
investigated in detail so far, but initial observations point to a higher risk of HFpEF in white women.
Eaton et al. conducted a comprehensive analysis of influence of race on HFpEF and HFrEF development,
as well as the role of various risk factors in each race [29]. The analysis was performed in a large
multiracial cohort of 42,170 postmenopausal women. The findings revealed that white race, and not
African American and Hispanic groups, was associated with both, HFpEF and HFrEF [29]. Obesity
was reported as a more important risk factor of HFpEF in African American women in comparison
with white women. There was some difference in the prevalence of potentially modifiable risk factors
among women with HFpEF [29]. In white women, about 66% of the population-attributable risk
percentage was related to hypertension and obesity, while diabetes and coronary artery disease made
up 25% of this risk [29]. For African American women, hypertension and obesity were associated
with >90% of the population-attributable risk percentage, whereas for Hispanic women, the same risk
factors were associated with approximately 72% of the population-attributable risk percentage [29].
A large cohort study which followed 12,417 participants for almost 12 years showed that the
lifetime risk of overall HF was higher in non-blacks than blacks [10]. The lifetime risk of HFpEF
development was approximately 1.5-fold higher in non-blacks as compared with blacks. Blacks had
a similar lifetime risk of HFpEF and HFrEF, whereas non-blacks had a higher risk of HFpEF than
HFrEF [10]. However, the authors did not present sex-specific analyses.
3.5. Other Risk Factors
Goyal et al. found that chronic renal and hepatic failure was more prevalent among men with
HFpEF [6]. Harada et al. confirmed these findings in HFpEF patients [7]. Another recent study
reported that anemia was an independent predictor of all-cause mortality in women with HFpEF, but
not in those with HFrEF [44]. On the other hand, Duca et al. did not find any difference whatsoever in
the prevalence of chronic kidney disease between women and men with HFpEF [8].
Anemia was described as an additional risk factor of HFpEF development in women, but not
in men [6]. Eaton et al.—in a large study that included only postmenopausal women—reported that
anemia was an independent predictor of HFpEF occurrence in African American women, but not in
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white women [29]. There have also been studies that showed a borderline higher prevalence of anemia
among men with HFpEF [8].
Chronic pulmonary obstructive disease represents a risk factor of HFpEF in both sexes. Goyal et al.
showed that it is more prevalent in men with HFpEF older than 75 years of age, and in women
with HFpEF younger than 75 years of age [6]. Eaton et al. found that chronic lung disease was an
independent predictor of HFpEF only in white, but not in African American and Hispanic women [29].
Duca et al. reported higher prevalence of chronic obstructive pulmonary disease in men with HFpEF [8].
In a population of older patients who underwent radiation therapy due to breast cancer, cardiac
radiation exposure increased the risk of HFpEF development, and the higher mean cardiac radiation
dose was associated with a greater risk of HFpEF [45]. The radiation was associated more strongly
with HFpEF than with HFrEF occurrence.
In summary, the pathophysiological studies available so far consistently show that obesity,
hypertension, and diabetes have sex-specific effects in HFpEF, whereas for other risk factors, there is
some evidence, but it is not so clear.
4. Clinical Studies
In the last few years, important studies regarding hemodynamic changes and LV remodeling
in HFpEF have been published [7,37,46,47]. However, only a small portion have been devoted to
sex-related changes [7,47]. Our study group has recently published data regarding the diagnosis of
HFpEF using diastolic stress echocardiography testing, which also partly illuminates the hemodynamic
changes typical of HFpEF [48].
4.1. Hemodynamic Changes and Cardiovascular Remodeling
A recently published study found that women with HFpEF had worse diastolic reserve, estimated
by: (i) elevated LV filling pressures measured by echocardiographic and invasive measurements at
exercise; (ii) lower systemic and pulmonary arterial compliance; and (iii) worse peripheral oxygen
kinetics [47]. This elegant investigation included 161 HFpEF subjects (114 females and 47 males) who
had already been diagnosed and treated for HFpEF. The authors performed right heart catheterization
and revealed that females had a higher pulmonary capillary wedge pressure indexed to peak exercise
workload, and lower systemic and pulmonary arterial compliance at exercise [47]. Interestingly, the
significant difference in right atrial pressure, pulmonary artery pressure, wedge pressure, stroke
volume, and stroke volume index between the sexes was not present at rest [47]. Only through
exercise was it possible to reveal increased LV filling pressures in women, but not in men with HFpEF.
Echocardiographic findings demonstrated differences between the sexes at rest. Women had higher
LV filling pressure, evaluated by E/e’ ratios at rest, and more pronounced at peak exercise, together
with a higher LVEF and smaller ventricular dimensions [47]. On the other hand, mitral E/A ratio was
similar between the sexes at rest and during exercise. Women showed significantly higher systemic
and pulmonary vascular resistance levels (indexed to BSA (Body surface area)) both at rest and
during exercise [47]. Correspondingly, both systemic and pulmonary compliance levels were lower
in women at rest and during exercise. Arterial elastance was significantly higher in women during
exercise in comparison with men, although statistical significance vanished after indexing to BSA [47].
Ventricular–vascular coupling was reduced in women compared to in men after indexing to BSA at rest
and after exercise. However, the difference in ventricular–vascular coupling did not reach statistical
significance after exercise. The authors did not report significant sex differences between baseline or
exercise in mixed venous oxygen saturation, arteriovenous oxygen differences, oxygen consumption
levels, or oxygen exchange ratios [47].
This study agrees with our findings that showed usefulness of diastolic stress echocardiography in
discovering HFpEF patients in the individuals with dyspnea on exertion in simple clinical settings [48],
without the use of right heart catheterization and comprehensive blood gas analysis.
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Duca et al. did not find any difference in invasive hemodynamic parameters between women
and men with HFpEF, except borderline higher wedge pressure in women and significantly increased
diastolic pressure gradient in men [8].
The PARAMOUNT trial (Prospective comparison of ARNi with ARB on management of heart
failure with preserved ejection fraction) was the first investigation that provided a detailed sex-specific
analysis of LV structure, function, and mechanics in HFpEF [37]. As expected, LV mass and volumes
indexed for body size were significantly lower in women with HFpEF. However, left atrial volumes
indexed for height and LVEF were significantly higher in women [37]. There was no difference in
mitral E/A ratio, but E/e’ was significantly higher in women [37]. Interestingly, there was no difference
in LV longitudinal, circumferential, and radial strain between the women and men with HFpEF [37].
The authors showed a trend towards abnormal LV geometry (concentric remodeling, eccentric and
concentric LV hypertrophy) in women, but not in men. The authors reported that effective arterial
elastance, LV end systolic elastance, and diastolic stiffness were higher among women with HFpEF,
whereas ventricular–vascular coupling was similar between the sexes [37].
Harada et al. reported similar findings regarding smaller LV and better LVEF in women with
HFpEF, but E/e’ ratio was similar between the sexes and the left atrium was larger in men [7]. Concentric
LV hypertrophy was predominant in women, whereas eccentric LV hypertrophy was more prevalent in
men with HFpEF [7]. The findings from hemodynamic and echocardiographic studies are summarized
in Table 2.
Table 2. Sex-specific differences in hemodynamic changes and cardiovascular remodeling in
HFpEF patients.
Reference Sample Size Women/Men (%) Study Type Main Findings
Beale et al.
[47] 161 HFpEF pts 114 (71) Cross-sectional
Women with HFpEF had worse diastolic
reserve. LV filling pressures measured by
echocardiographic and invasive measurements
at exercise were higher than in men. Women
showed lower systemic and pulmonary arterial
compliance, as well as worse peripheral
oxygen kinetics.
Harada et al.
[7] 733 HFpEF pts 529 (72) Cross-sectional
Females with HFpEF had smaller LV diameters
and better LVEF. LV filling pressure was similar
between sexes. Left atrium was larger in men.
Concentric LV hypertrophy was predominant
in women, and eccentric in men with HFpEF.
Duca et al. [8] 260 HFpEF pts 181 (70) 30 monthfollow-up
No difference in invasive hemodynamic
parameters between women and men with
HFpEF. LV mass index was significantly higher
in men, and LVEF measured by CMR was
significantly higher in women.
Gori et al.
[37] 279 HFpEF pts 159 (57)
3 year
follow-up
Indexed LV mass and volumes were
significantly lower in women with HFpEF.
Indexed left atrial volume, LVEF and LV filling
pressure were significantly higher in men.
There was no difference in LV longitudinal,
circumferential, and radial strain between
women and men with HFpEF. Effective arterial
elastance, LV end systolic elastance and
diastolic stiffness were higher among women
with HFpEF.
HFpEF—heart failure with preserved ejection fraction, LV—left ventricle.
4.2. Outcomes
Goyal et al. demonstrated that women with HFpEF had lower in-hospital mortality compared
with men (4.2% vs. 4.6%, p < 0.001) [6]. Interestingly, the sex difference in mortality was only seen in
women older than 75 years of age, whereas women younger than 75 years of age had similar mortality
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as men. The TOPCAT trial showed no difference in outcomes (cardiovascular and all-cause mortality),
or in hospitalization due to heart failure, between women and men with HFpEF [9].
Nakada et al. revealed that the incidence of cardiovascular death and admission due to HF tend
was lower in female than in male HFpEF patients, but the difference was not statistically significant [36].
A small cohort study that involved 260 HFpEF patients and followed them for 30 months showed that
men had higher rates of cardiac death (16.5% vs. 6.1%, p = 0.008) and lower rates of non-cardiac death
(2.5% vs. 10.5%, p = 0.030) in comparison with women [8]. Male sex was independently associated
with cardiac death. An investigation that included 4161 HFpEF patients (67% women) hospitalized
due to HF symptoms demonstrated no difference between women and men in in-hospital mortality, as
well as in 30 day and 180 day outcomes [49]. Hsich et al. involved 37,699 patients with HFpEF (65%
women and 35% men), and did not find any sex difference in in-hospital mortality (2.61% in women vs.
2.62% in men, p = 0.96) [50].
5. Treatment
There is no current consensus on the optimal therapy for HFpEF, and it is unknown if it should
be treated in the same way as HFrEF or as a completely different entity. The data on this topic
are scarce, and there is even less knowledge of the benefit of sex-specific therapy in HFpEF. Our
study group recently summarized the sex-specific therapeutic approach to arterial hypertension [51].
Considering the fact that hypertension represents almost “sine qua non” in the HFpEF continuum, this
approach could serve as a good starting point for sex-specific treatment of HFpEF. Table 3 shows known
pathophysiological mechanisms responsible for higher prevalence of HFpEF among women (hormonal,
bio-hormonal, risk factors, and race), as well as potential targets for therapy in these patients.
Table 3. Summarized pathophysiology and therapy in women with HFpEF.
Hormonal Bio-Hormonal Risk Factors Race Therapy
Decreased
estradiol
Higher angiotensin-converting
enzyme serum activity in
women
Obesity White race, and not African American
and Hispanic, was associated with
HFpEF
Spironolactone-associated reduction in all-cause
mortality was observed only in women
Hypertension
Higher
testosterone
Increased sympathetic
nervous system activity in
women
Diabetes Obesity was reported as more
important risk factor in African
American women
Sex-specific differences regarding beta blockers
and renin-angiotensin inhibitors in HFpEF have
not been investigated so farCoronary heart disease
Decreased nitric oxide
bioavailability
Atrial fibrillation
Anemia
Increased prostaglandin and
prostacyclin levels
Chronic obstructive
pulmonary disease
Oxidative stress
Renal dysfunction
Chemo- and
radiotherapy
HFpEF—heart failure with preserved ejection fraction.
The TOPCAT trial showed that spironolactone had a similar effect on the primary outcome in
HFpEF in both sexes [9]. However, spironolactone-associated reduction in all-cause mortality was
observed only in women, with a significant interaction between the sex and the treatment arm [9].
Several studies did not report differences in the prevalence of different medications between women
and men with HFpEF [7,8], even though Harada et al. showed a higher prevalence of beta-blocker use
in men with HFpEF [7]. However, these investigations were not designed to investigate the influence
of different medications on the outcome in HFpEF.
A large meta-analysis that included 28,636 HFpEF patients (35–70% women) showed a significant
benefit from the use of beta-blockers on all-cause mortality in observational studies, with a reduction
in mortality by 21% in HFpEF patients, irrespective of sex [52]. However, this was not confirmed in
randomized trials [52].
Khan et al. used the data of randomized trials involving 17,284 HFpEF patients to investigate the
effect of ACE inhibitors and angiotensin receptor blockers on outcome [53]. In this pooled analysis,
RAAS inhibitors did not show any effect on all-cause mortality, while the results from observational
studies showed a significant improvement. In pooled analyses of all studies, angiotensin-converting
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enzyme inhibitors showed a reduction of all-cause mortality [53]. There was no reduction in
cardiovascular mortality; however, in the pooled analysis of randomized trials, there was a trend
towards reduced HF hospitalization risk, but it did not reach any statistical significance [53].
Spironolactone has been shown to improve functional capacity and LV diastolic function in a
study of HFpEF patients [54]. However, a sex-specific subanalysis was not performed in this study.
Another small prospective observational study showed no correlation between soluble neprilysin
and outcome in patients with HFpEF [55]. The PARAGON-HF trial (Prospective Comparison of
Angiotensin Receptor Neprilysin Inhibitor with Angiotensin Receptor Blocker Global Outcomes in
HFpEF) was designed to compare the effects between sacubitril/valsartan and valsartan in reducing
morbidity and mortality in HFpEF [56].
6. Conclusions
HFpEF represents the most prevalent form of HF in women, which is associated with adverse clinical
outcomes. HFpEF has unique pathophysiology in women related to certain comorbidities and specific
cardiovascular remodeling. Some risk factors such as arterial hypertension, obesity, diabetes mellitus,
coronary artery disease, atrial fibrillation, and race have specific features that might be responsible for
a particular phenotypic profile in women with HFpEF. These risk factors are associated with specific
cardiovascular changes—left ventricular diastolic dysfunction and hypertrophy, ventricular–vascular
coupling, and impaired functional capacity—that are related to particular cardiac phenotype and HFpEF
development. Sex hormones are still considered to have the leading role in sex-specific cardiovascular
remodeling, including HFpEF. There is no agreement regarding outcome in women with HFpEF.
Sex-specific HFpEF treatment is far from a reality at this moment, but it represents a very important future
direction toward personalized medicine. A majority of the studies that have investigated the outcome
or treatment in HFpEF patients did not aim to research the differences between the sexes. Therefore,
longitudinal studies with sex-specific outcomes as the primary aim should be conducted.
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